Biomarkers for Alzheimer's disease trials - Biomarkers for what? A discussion paper

Journal of Nutrition, Health and Aging

Volumn 13, Issue 4, 2009, Pages 334-336

  Lovestone, S ^a   Thambisetty, M ^b  

^a King s College London   (United Kingdom)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID A PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; LEWY BODY; MULTIINFARCT DEMENTIA; NEUROIMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; RESEARCH DESIGN;

EID: 65249139894     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-009-0033-x     Document Type: Article

References (5)

1. Alzheimers Assoc, Natl Inst Aging. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 1998; 19: 109-116.
2. Foy CM, Nicholas H, Hollingworth P et al. Diagnosing Alzheimer's disease - nonclinicians and computerised algorithms together are as accurate as the best clinical practice. Int J Geriatr Psychiatry 2007; 22:1154-1163.
3. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734-46.
4. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Neurology. 2007;69(24):2197-204. Mixed brain pathologies account for most dementia cases in community-dwelling older persons.
5. Holmes C, Boche D, Wilkinson D et al. Lancet. 2008; 372(9634):216-23. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial